086040 — Biotoxtech Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapSucker Stock

Market Cap
KR₩49bn
Enterprise Value
KR₩86bn
Revenue
KR₩41bn

Annual income statement for Biotoxtech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	26,429	32,717	37,292	32,631	41,341
Cost of Revenue
Gross Profit	6,436	10,546	12,480	1,899	2,557
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	25,891	28,086	36,312	40,855	49,859
Operating Profit	537	4,632	979	-8,224	-8,517
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,245	6,485	-644	-11,833	-8,822
Provision for Income Taxes
Net Income After Taxes	2,367	6,698	64.7	-8,950	-12,657
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	2,614	7,114	2,725	-4,878	-6,427
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,614	7,114	2,725	-4,878	-6,427
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	180	446	82.9	-314	-419
Dividends per Share